TP53 and acute myeloid leukemia: Of note, recent work has reported the cooperative induction of endogenous retroviruses by DAC in combination with ATRA, in AML cell lines of different TP53 status,[30] lending further support to the implementation of ATRA in the first‐line treatment for p53‐mutant patients.[31] Consistently, we found that the combination of DAC and ATRA caused more cell death (Figure 3V) and induced more endogenous retroviruses dsRNA such as ERVL (Figure 3W) in cells with mutant p53 than wild‐type p53.